Crohn's disease: increased mortality 10 years after diagnosis in a Europe-wide population based cohort

Wolters, F. L.; Russell, M. G.; Sijbrandij, J.; Schouten, L. J.; Odes, S.; Riis, L.; Munkhom, P.; Bodini, P.; O'Morain, C.; Mouzas, I. A.; Tsianos, E.; Vermeire, S.; Monteiro, E.; Limonard, C.; Vatn, M.; Fornaciari, G.; Pereira, S.; Moum, B.; Stockbrügger, R. W.
April 2006
Gut;Apr2006, Vol. 55 Issue 4, p510
Academic Journal
Background: No previous correlation between phenotype at diagnosis of Crohn's disease (CD) and mortality has been performed. We assessed the predictive value of phenotype at diagnosis on overall and disease related mortality in a European cohort of CD patients. Methods: Overall and disease related mortality were recorded 10 years after diagnosis in a prospectively assembled, uniformly diagnosed European population based inception cohort of 380 CD patients diagnosed between 1991 and 1993. Standardised mortality ratios (SMRs) were calculated for geographic and phenotypic subgroups at diagnoses. Results: Thirty seven deaths were observed in the entire cohort whereas 21.5 deaths were expected (SMR 1.85 (95% CI 1.30-2.55)). Mortality risk was significantly increased in both females (SMR 1.93 (95% CI 1.10-3.14)) and males (SMR 1.79 (95% CI 1.11-2.73)). Patients from northern European centres had a significant overall increased mortality risk (SMR 2.04 (95% CI 1.32-3.01)) whereas a tendency towards increased overall mortality risk was also observed in the south (SMR 1.55 (95% CI 0.80-2.70)). Mortality risk was increased in patients with colonic disease location and with inflammatory disease behaviour at diagnosis. Mortality risk was also increased in the age group above 40 years at diagnosis for both total and CD related causes. Excess mortality was mainly due to gastrointestinal causes that were related to CD. Conclusions: This European multinational population based study revealed an increased overall mortality risk in CD patients 10 years after diagnosis, and age above 40 years at diagnosis was found to be the sole factor associated with increased mortality risk.


Related Articles

  • Predictors and risks for death in a population-based study of persons with IBD in Manitoba. Bernstein, Charles N.; Nugent, Zoann; Targownik, Laura E.; Singh, Harminder; Lix, Lisa M. // Gut;Sep2015, Vol. 64 Issue 9, p1403 

    Background and aims We aimed to determine the predictors and risk for death among persons with either Crohn's disease (CD) or UC compared with the general population. Methods We used the population-based University of Manitoba IBD Epidemiology Database to calculate HRs and their 95% CIs for...

  • Small bowel resection rates in Crohn's disease and the indication for surgery over time: experience from a large tertiary care center.  // Inflammatory Bowel Disease Monitor;2010, Vol. 11 Issue 2, p84 

    The article looks into the result of the study which investigates the significant changes of the rate and indication for small-bowel resection presented on the Crohn's disease patients at the University of Pittsburgh Medical Center in Pittsburgh, Pennsylvania.

  • Predicting prognosis in patients with inflammatory bowel disease.  // Biomedical Market Newsletter;9/30/2011, Vol. 21, p436 

    The article offers information on the gene expression profile discovered by researchers that could predict prognosis in patients with Crohn's disease (CD) and ulcerative colitis (UC).

  • Cytomegalovirus Pneumonia: A Possible Cause of Death in Patients With Crohn's Disease. Cascio, Antonio; Iaria, Chiara; Fries, Walter // American Journal of Gastroenterology;Mar2013, Vol. 108 Issue 3, p454 

    A letter to the editor is presented in response to the research paper related to mortality and infection in patients suffering Crohn's Disease (CD) by G.R. Lichtenstein, B.G. Feagan and R.D. Cohen. in a previous issue.

  • Consumption of Dental Treatment in Patients with Inflammatory Bowel Disease, a Register Study. Johannsen, Annsofi; Fored, Michael C.; Håkansson, Jan; Ekbom, Anders; Gustafsson, Anders // PLoS ONE;8/12/2015, Vol. 10 Issue 8, p1 

    Objective: The aim of this study was to compare the consumption of dental treatment among patients with Crohn´s disease (CD) or ulcerative colitis (UC) compared to age and gender matched control groups. Design: The study group comprised 2085 patients with CD and 3161 with UC from the...

  • Detection of DNA hypermethylation in sera of patients with Crohn's disease. JIN-HAN BAE; JONGHA PARK; KWANG MO YANG; TAE-OH KIM; JOO MI YI // Molecular Medicine Reports;2014, Vol. 9 Issue 2, p725 

    Mounting evidence suggests that inflammatory bowel disease (IBD) is caused by genetic predisposition of various genes as well as an abnormal interaction with environmental factors, resulting in epigenetic alterations. It has become evident that epigenetic factors play a significant contributory...

  • Immunization status in children with inflammatory bowel disease. Longuet, Romain; Willot, Stephanie; Giniès, Jean-Louis; Pélatan, Cecile; Breton, Estelle; Segura, Jean-François; Bridoux, Laure; Henaff, Gaelle; Cagnard, Benoit; Jobert, Agathe; Cardonna, Joël; Grimal, Isabelle; Balençon, Martine; Darviot, Estelle; Delaperrière, Nadège; Caldari, Dominique; Piloquet, Hugues; Dabadie, Alain // European Journal of Pediatrics;May2014, Vol. 173 Issue 5, p603 

    Inflammatory bowel diseases have an increased risk of infections due to immunosuppressive therapies. To report the immunization status according to previous recommendations and the reasons explaining a delay, a questionnaire was filled in by the pediatric gastroenterologist, concerning...

  • Crohn's disease: why the disparity in mortality? Loftus Jr., E. V. // Gut;Apr2006, Vol. 55 Issue 4, p447 

    The article comments on a study conducted by F.L. Wolters and colleagues titled "Crohn's Disease: Increased Mortality 10 Years After Diagnosis in a Europe-Wide Population-Based Cohort." The author cites the strengths and weaknesses of the EC-IBD mortality study. He also compares the EC-IBD study...

  • Sustained remission in patients with Crohn's disease.  // British Journal of Hospital Medicine (17508460);Jul2009, Vol. 70 Issue 7, p377 

    The article reports on the remission in patients with Crohn's disease to three years of therapy. It mentions that 64 percent of adalimumab-treated patients who were in remission after a year in the CHARM study remains in remission at the end of two additional years in the open label extension....


Read the Article


Sign out of this library

Other Topics